Metagenomi Therapeutics, Inc. Share Price

Metagenomi Therapeutics, Inc. Share Price

NASDAQ: MGX | Micro Cap
$0.85
+$0.01 (1.70%) Last updated on 29 Oct, 2026 | 22:26 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Metagenomi Therapeutics, Inc. Stock Performance

Open
$0.85
Prev. Close
$0.83
Circuit Range
N/A
Day Range
$0.85 - $0.85
Year Range
$0.77 - $2.60
Volume
202
Average Traded
$0.85

Metagenomi Therapeutics, Inc. Share Price Today

As of 30 October 2026, Metagenomi Therapeutics, Inc.'s share price is $0.85. The stock opened at $0.85, compared to its previous close of $0.83. During today's trading session, Metagenomi Therapeutics, Inc.'s share price traded between $0.85 and $0.85, with an average price of $0.85. Over the past 52 weeks, the stock has recorded a high of $2.60 and a low of $0.77. In terms of performance, Metagenomi Therapeutics, Inc.'s share price has declined by 38.60% over the last six months and is down 66.58% on a year-on-year basis.

Metagenomi Therapeutics, Inc. Share Price Chart

Line chart of the Metagenomi Therapeutics, Inc. price trend over the selected period. The price rose overall, ranging from 0.85 to 0.85, ending at 0.85.
$0.85$0.85
L
Show Current Price
H

Metagenomi Therapeutics, Inc. Stock Fundamentals & Key Indicators

Market Cap
$31.56M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-2.47
Revenue (TTM)
$25.21B
Return On Equity (TTM)
-83.03%
Profit Margin
-348.55%
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-34.77%

Metagenomi Therapeutics, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$8.66$3.91$1.25-$0.26
Net Profit-$20.39-$22.53-$23.06-$27.48
Net Profit Margin-235.45%-576.21%-1844.80%10569.23%
Income ChangeN/A-10.50%-2.35%-19.17%

Metagenomi Therapeutics, Inc. Annual Profit & Loss

All figures in USD

Particulars20242025
Revenue$52.30$25.21
Net Profit-$78.06-$87.87
Net Profit Margin-149.25%-348.55%
Income ChangeN/A-12.57%

About Metagenomi Therapeutics, Inc.

Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.

Metagenomi Therapeutics, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$1.08
$0.85
-20.19%
Sep 2026
$1.18
$1.07
-11.57%
Aug 2026
$1.23
$1.21
+1.68%
Jul 2026
$1.18
$1.19
+0.42%
Jun 2026
$1.33
$1.19
-13.50%
May 2026
$1.34
$1.37
-0.72%
Apr 2026
$1.37
$1.38
+3.76%
Mar 2026
$1.49
$1.33
-13.07%
Feb 2026
$1.52
$1.53
-0.65%
Jan 2026
$1.64
$1.54
-5.23%
Dec 2025
$1.70
$1.63
-7.93%
Nov 2025
$2.54
$1.76
-30.37%

MGX Share Price FAQs